NCT06247488 - Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users | Biotech Hunter

Enrollment

110

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

April 25, 2023

Study Completion Date

April 25, 2023

Conditions

Abuse Potential

Interventions

DRUG

Placebo

Participant will receive oral dose of placebo.

DRUG

Oxycodone 20 mg

Participant will receive oral dose of oxycodone 20 mg.

DRUG

GE-IR 200 mg

Participant will receive oral dose of GE-IR 200 mg and oxycodone 20 mg.

DRUG

GE-IR 450 mg

Participant will receive oral dose of GE-IR 450 mg and oxycodone 20 mg.

Trial Locations (1)

Altasciences Clinical Kansas, Overland Park